- Home
- PHD vs CTNM Comparison
PHD vs CTNM Comparison
Compare PHD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHD
- CTNM
- Stock Information
- Founded
- PHD 2004
- CTNM 2009
- Country
- PHD United States
- CTNM United States
- Employees
- PHD N/A
- CTNM N/A
- Industry
- PHD Investment Managers
- CTNM
- Sector
- PHD Finance
- CTNM
- Exchange
- PHD Nasdaq
- CTNM Nasdaq
- Market Cap
- PHD 120.3M
- CTNM 114.1M
- IPO Year
- PHD N/A
- CTNM 2024
- Fundamental
- Price
- PHD $9.77
- CTNM $4.41
- Analyst Decision
- PHD
- CTNM Strong Buy
- Analyst Count
- PHD 0
- CTNM 4
- Target Price
- PHD N/A
- CTNM $22.50
- AVG Volume (30 Days)
- PHD 67.7K
- CTNM 124.3K
- Earning Date
- PHD 01-01-0001
- CTNM 05-14-2025
- Dividend Yield
- PHD 11.43%
- CTNM N/A
- EPS Growth
- PHD N/A
- CTNM N/A
- EPS
- PHD 1.27
- CTNM N/A
- Revenue
- PHD N/A
- CTNM N/A
- Revenue This Year
- PHD N/A
- CTNM N/A
- Revenue Next Year
- PHD N/A
- CTNM N/A
- P/E Ratio
- PHD $7.60
- CTNM N/A
- Revenue Growth
- PHD N/A
- CTNM N/A
- 52 Week Low
- PHD $8.30
- CTNM $3.35
- 52 Week High
- PHD $9.81
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- PHD 65.13
- CTNM N/A
- Support Level
- PHD $9.72
- CTNM N/A
- Resistance Level
- PHD $9.78
- CTNM N/A
- Average True Range (ATR)
- PHD 0.06
- CTNM 0.00
- MACD
- PHD -0.01
- CTNM 0.00
- Stochastic Oscillator
- PHD 83.33
- CTNM 0.00
About PHD Pioneer Floating Rate Fund Inc.
Pioneer Floating Rate Trust is a diversified, closed-end fund. It invests in the fixed income markets of the United States. The fund basically invests in senior secured floating-rate loans. It benchmarks the performance of its portfolio against the other High Yield Loans Index banks.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.